Oncotype DX AR-V7 Nucleus Detect liquid biopsy test – pro
Patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) have a new tool to help guide their treatment. The new Oncotype DX AR-V7 Nucleus Detect liquid biopsy test identifies whether a patient’s disease will respond to commonly prescribed androgen receptor (AR)-targeted drugs such as XTANDI® or ZYTIGA® , or whether the patient should consider chemotherapy or other therapies.
The Oncotype DX AR-V7 test is a blood test that purports to accurately identify AR-V7 proteins in the nucleus of circulating tumor cells. A positive result means the patient will not respond to AR-targeted therapies and should consider chemotherapy or other treatments. A negative result means the patient may benefit from another AR-therapy. This test is not prospectively validated and not recommended by standard national guidelines.
Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016;2(11):1441-1449.
NCCN Prostate 2018